Advancing Diabetes Research and Care with Digital Education and Knowledge Sharing
Pharm Fresh: What Pharmacological Solutions Could Play a Role in Preventing Diabetes?
Cutting-edge advancements in endocrinology continue to move diabetes treatment in the right direction faster than ever before. The treatment of diabetes is continually evolving. More than a century ago, a diabetes diagnosis was a death sentence, and although there is not yet a cure, endless updates in diabetes care help ease the burden of both...
FDA Approves Lilly’s Zepbound™ (tirzepatide) for Chronic Weight Management
On November 8, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who...
Software Company Simplifies Glycemic Management for Clinicians and Pharmacists
In August, the insulin management software company Glytec unveiled the latest version of its Glucommander insulin dosing software to make it easier for providers, nurses, and pharmacists to offer optimal, personalized care. More than 300 hospitals in the U.S. use Glytec’s eGlycemic Management System® (eGMS®) for glycemic management for their patients. Glytec chief medical officer...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information.* New Clinical Data Point to Use of GlycoMark as Biomarker of SGLT-2 Diabetes Drug Effectiveness and Compliance Precision Diabetes, Inc. announces new studies that show that the GlycoMark blood test, which measures 1,5-anhydroglucitol, may be useful for evaluating short-term effectiveness and assessing...